Skip to Content
MilliporeSigma

P0018

Pomalidomide

≥98% (HPLC), powder, HbF inducer

Synonym(s):

1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline, 3-amino-N-(2,6-dioxo-3-piperidyl)phthalamide, 4-Amino-2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione, Actimid, CC-4047, IMiD 3

Slide 1 of 1
Sign In to View Organizational & Contract Pricing

Select a Size

5 MG

$162.00

25 MG

$673.00

$162.00

Available to ship TODAYDetails

Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C13H11N3O4
CAS Number:
19171-19-8
Molecular Weight:
273.24
MDL number:
MFCD12756407
UNSPSC Code:
12352200
PubChem Substance ID:
329819974
NACRES:
NA.77

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Pomalidomide, ≥98% (HPLC)

ligand

pomalidomide

Quality Level

100

assay

≥98% (HPLC)

form

powder

reaction suitability

reagent type: ligand

color

yellow

solubility

DMSO: ≥14 mg/mL

storage temp.

2-8°C

SMILES string

Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12

InChI

1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)

InChI key

UVSMNLNDYGZFPF-UHFFFAOYSA-N

Gene Information

human ... CRBN(51185), CUL4A(8451), DDB1(1642), RBX1(9978)

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
930563SML2283930571
Pomalidomide ≥98% (HPLC)

Sigma-Aldrich

P0018

Pomalidomide

Pomalidomide-PEG2-C2-azide ≥95%

Sigma-Aldrich

930563

Pomalidomide-PEG2-C2-azide

Lenalidomide ≥98% (HPLC)

Sigma-Aldrich

SML2283

Lenalidomide

Pomalidomide-piperidine-carboxylic acid ≥95%

Sigma-Aldrich

930571

Pomalidomide-piperidine-carboxylic acid

assay

≥98% (HPLC)

assay

≥95%

assay

≥98% (HPLC)

assay

≥95%

form

powder

form

powder

form

powder

form

powder

Quality Level

100

Quality Level

100

Quality Level

-

Quality Level

100

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

DMSO: ≥14 mg/mL

solubility

-

solubility

DMSO: 2 mg/mL, clear

solubility

-

color

yellow

color

-

color

white to beige

color

-

Application

Pomalidomide has been used:
  • to treat BV173 cells to study the role of proteolysis targeting chimera (PROTAC) compound, JQ1-CRBN, in inducing specific class-I major histocompatibility complex (MHC-I) peptides[1]
  • for apoptosis studies and intracellular calcium analysis[2]
  • as a fetal hemoglobin (HbF) agent to study the additive effect with UNC0638 on the levels of fetal hemoglobin expression in β-thalassemia/ variant hemoglobin E (HbE) erythroid progenitor cells[3]

Biochem/physiol Actions

Pomalidomide is a second generation immunomodulator, TNF-α inhibitor, and thalidomide analog.
Pomalidomide is an effective fetal hemoglobin (HbF) inducer that downregulates the key &#947-globin repressors, SRY-box transcription factor 6 (SOX6), and BAF chromatin remodeling complex subunit (BCL11A).[3]

Features and Benefits

This compound is featured on the Cytokine Receptors (Tumor Necrosis Receptor Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

related product

Product No.
Description
Pricing

901494

N-Methylated pomalidomide, ≥98%

901495

Pomalidomide-PEG3-NH2 hydrochloride, ≥95%

901496

Pomalidomide-C6-CO2H, ≥98%

901500

Pomalidomide-C3-CO2H, ≥95%

901504

Pomalidomide-PEG3-CO2H, ≥95%

901516

Pomalidomide-PEG1-NH2 hydrochloride, ≥95%

901513

Pomalidomide-PEG2-NH2 hydrochloride, ≥95%

901523

Pomalidomide-PEG1-Alkyne, ≥98%

901531

Pomalidomide-PEG3-Alkyne, ≥95%

901529

Pomalidomide-PEG2-Alkyne, ≥95%

901527

Pomalidomide-PEG1-CO2H, ≥95%

901526

Pomalidomide-PEG2-CO2H, 95%

901525

Pomalidomide-C9-CO2H, ≥95%

901558

Lenalidomide, ≥95%

901835

Pomalidomide-PEG6-Alkyne

901834

Pomalidomide-PEG5-Alkyne, ≥95%

901833

Pomalidomide-PEG4-Alkyne

901830

Pomalidomide-PEG4-NH2 hydrochloride, ≥95%

901829

Pomalidomide-PEG6-CO2H

901828

Pomalidomide-PEG5-CO2H, ≥95%

901824

Pomalidomide-PEG4-CO2H

901860

(S,R,S)-AHPC-PEG6-NH2 hydrochloride, ≥95%

903434

Pomalidomide-PEG6-butyl azide, ≥95%

903442

Pomalidomide-PEG6-butyl iodide, ≥95%

903833

Pomalidomide-PEG2-azide

903825

Pomalidomide-PEG1-azide

903957

(S,R,S)-AHPC-PEG1-azide

904651

(S,R,S)-AHPC-PEG3-azide, ≥95%

904724

Pomalidomide-PEG2-butyl iodide, ≥95%

904708

Pomalidomide-C6-PEG3-butyl iodide, ≥95%

904678

Pomalidomide-PEG3-azide

904686

Pomalidomide-C6-PEG3-butyl azide, ≥95%

904813

(S,R,S)-AHPC-PEG2-azide

904821

(S,R,S)-AHPC-C6-PEG3-butyl azide, ≥95%

904880

Pomalidomide-C6-PEG1-C3-PEG1-butyl azide, ≥95%

904872

Pomalidomide-PEG2-butyl azide, ≥95%

904864

(S,R,S)-AHPC-PEG6-butyl azide, ≥95%

905224

Pomalidomide-PEG6-butyl amine hydrochloride, ≥95%

913979

Biotin-Thalidomide, ≥95%

919381

CCW16, ≥95%

924202

5-Amino-Thalidomide, ≥95%

pictograms

Health hazard
GHS08

signalword

Danger

hcodes

H360D

Hazard Classifications

Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000445339
0000445339
0000430870
0000430867
0000430867

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Suzanne Lentzsch et al.
Cancer research, 62(8), 2300-2305 (2002-04-17)
Thalidomide has recently been shown to be useful in the treatment of multiple myeloma and may also be useful in the treatment of other hematological malignancies. We have identified a new derivative of thalidomide, S-3-[3-amino-phthalimido]-glutarimide (S-3APG) with dual activity against
Emma C Fink et al.
Blood, 132(14), 1535-1544 (2018-08-02)
Thalidomide and its derivatives, lenalidomide and pomalidomide, are clinically effective treatments for multiple myeloma and myelodysplastic syndrome with del(5q). These molecules lack activity in murine models, limiting investigation of their therapeutic activity or toxicity in vivo. Here, we report the
Susana Hernández-García et al.
Haematologica, 102(12), 2113-2124 (2017-09-02)
Kinesin spindle protein inhibition is known to be an effective therapeutic approach in several malignancies. Filanesib (ARRY-520), an inhibitor of this protein, has demonstrated activity in heavily pre-treated multiple myeloma patients. The aim of the work herein was to investigate
Qian Jiang et al.
Cell death & disease, 8(10), e3146-e3146 (2017-10-27)
Mumps virus (MuV) infection usually results in germ cell degeneration in the testis, which is an etiological factor for male infertility. However, the mechanisms by which MuV infection damages male germ cells remain unclear. The present study showed that C-X-C
Craig T Wallington-Beddoe et al.
British journal of haematology, 182(1), 11-28 (2018-04-21)
The number of novel therapies for the treatment of myeloma is rapidly increasing, as are the clinical trials evaluating them in combination with other novel and established therapies. Proteasome inhibitors, immunomodulatory agents and monoclonal antibodies are the most well known
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service